Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Elanco Animal Health Inc reported the fiscal quarter ended September 30, 2023 results: revenue Revenue of $1,068 million, net income Reported Net Loss of $1,096 million, EPS Reported EPS of $(2.22).
- Period
- the fiscal quarter ended September 30, 2023
- Revenue
- Revenue of $1,068 million
- Net income
- Reported Net Loss of $1,096 million
- EPS
- Reported EPS of $(2.22)
- Result
- reported results
Exact text from the filing
Elanco Animal Health Reports Third Quarter 2023 Results • Third Quarter 2023 Financial Results ◦ Revenue of $1,068 million, representing 4% reported growth or 5% excluding the impact of foreign exchange rates ◦ Reported Net Loss of $1,096 million, inclusive of a non-cash goodwill impairment charge of $1,042 million primarily related to increased long-term treasury rates ◦ Adjusted EBITDA of $214 million, or 20.0% of Revenue ◦ Reported EPS of $(2.22) inclusive of a $(2.10) per share impact of goodwill impairment charge, Adjusted EPS of $0.18
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Elanco Animal Health Inc reported full year 2023 results: revenue Revenue of $4,360 to $4,400 million, net income Reported Net Loss of $1,174 to $1,204 million, EPS Reported diluted EPS of $(2.43) to $(2.37).
- Period
- full year 2023
- Revenue
- Revenue of $4,360 to $4,400 million
- Net income
- Reported Net Loss of $1,174 to $1,204 million
- EPS
- Reported diluted EPS of $(2.43) to $(2.37)
- Result
- guidance update
Exact text from the filing
Updating full year 2023 guidance to reflect third quarter outperformance offset by expected unfavorable impact of foreign exchange rates: ◦ Revenue of $4,360 to $4,400 million, constant currency growth improves to flat to 1% ◦ Reported Net Loss of $1,174 to $1,204 million, Reported diluted EPS of $(2.43) to $(2.37) ◦ Adjusted EPS of $0.88 to $0.94, Adjusted EBITDA of $965 to $1,000 million
View on SEC.gov